BPC-157 Capsules: Does Oral BPC-157 Survive Digestion?

Oral BPC-157 has a more interesting argument behind it than most oral peptide products. It is still an argument rather than a demonstration, and the distinction matters.

The case for oral BPC-157

Three points are usually made, and the first two are genuinely reasonable:

1. It derives from a gastric protein. BPC-157 is a synthetic fragment related to a protein found in gastric juice — so the argument runs that it evolved in, and is stable in, exactly the environment that destroys other peptides.

2. Much of the rodent research used oral administration. In a large number of Sikiric-group studies, BPC-157 was given in drinking water and effects were still observed — including in models of NSAID-induced gastrointestinal and liver injury.

3. It is short. Fifteen residues is small for a peptide, and smaller peptides are generally more robust than folded proteins.

The gap in the argument

There is no human pharmacokinetic data for BPC-157 by any route. No published study establishes its oral bioavailability in humans, its plasma concentration after an oral dose, or whether it reaches systemic circulation intact.

The last row is the crux. Many of the oral rodent studies used gastrointestinal injury models — where a compound acting locally on gut tissue would produce exactly the observed result without any systemic absorption. That does not disprove absorption; it means those studies cannot distinguish the two.

Why it matters which one is true

If oral BPC-157 acts locally in the gut, then oral dosing is reasonable for gut-related research questions and irrelevant for a tendon or joint. If it is absorbed systemically, oral dosing is broadly relevant. Nothing published resolves this in humans.

What the gut does to peptides generally

For context on why the question is hard, unmodified peptides face stomach acid, pepsin, trypsin and chymotrypsin, brush-border peptidases, an epithelial barrier and first-pass hepatic metabolism. Research into oral GLP-1 delivery has required elaborate engineering — lipid-based formulations combined with enteric capsules, for instance — precisely because none of it is easy.

BPC-157 may genuinely be more robust than a typical peptide. "More robust" and "orally bioavailable at a useful level in humans" are different claims, and only the first has support. The oral peptides guide covers the general problem.

Buying considerations

Oral BPC-157 products carry the verification problems of the injectable market plus some of their own:

• Capsule contents are harder to verify than a lyophilised vial — excipients complicate the analysis.

• "Enteric coated" or "stabilised" claims are rarely accompanied by data showing the coating does anything.

• Arginate salt forms are commonly marketed as more stable. This is a plausible formulation claim, not a demonstrated bioavailability result.

• Dose comparisons across routes are guesswork without bioavailability data for either.

• BPC-157 is an FDA Category 2 bulk substance, so a "pharmacy-grade" or "compounded" oral product describes something with no lawful route to exist. See the grey market guide.

See the BPC-157 dosage guide, the BPC-157 side effects guide and the peptide supplements guide.